OMERS ADMINISTRATION Corp Grows Stock Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)

OMERS ADMINISTRATION Corp grew its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 637.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 159,535 shares of the company's stock after acquiring an additional 137,888 shares during the period. OMERS ADMINISTRATION Corp's holdings in Dr. Reddy's Laboratories were worth $2,519,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Mercer Global Advisors Inc. ADV lifted its holdings in Dr. Reddy's Laboratories by 3.1% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 27,419 shares of the company's stock worth $433,000 after purchasing an additional 831 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Dr. Reddy's Laboratories by 423.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock worth $29,000 after buying an additional 1,507 shares in the last quarter. Glass Jacobson Investment Advisors llc boosted its position in shares of Dr. Reddy's Laboratories by 400.0% in the fourth quarter. Glass Jacobson Investment Advisors llc now owns 2,000 shares of the company's stock valued at $32,000 after acquiring an additional 1,600 shares during the period. POM Investment Strategies LLC grew its stake in Dr. Reddy's Laboratories by 400.0% during the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock valued at $36,000 after acquiring an additional 1,820 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in Dr. Reddy's Laboratories by 461.0% during the 4th quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock worth $40,000 after acquiring an additional 2,093 shares during the period. 3.85% of the stock is owned by institutional investors.

Dr. Reddy's Laboratories Stock Up 0.4%

Shares of NYSE RDY opened at $14.16 on Thursday. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The business has a 50-day moving average of $13.36 and a 200-day moving average of $14.05. The firm has a market capitalization of $11.82 billion, a price-to-earnings ratio of 22.55 and a beta of 0.33. Dr. Reddy's Laboratories Limited has a 12 month low of $12.26 and a 12 month high of $16.89.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The company reported $0.22 EPS for the quarter, topping analysts' consensus estimates of $0.20 by $0.02. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. The firm had revenue of $996.17 million for the quarter, compared to analyst estimates of $83.70 billion. Sell-side analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.